“…and to the delivery of anticancer drugs in resistant cells (see section 4.2.2.3.). The strength of a large body of works done with PACA nanoparticles strands on studies based on clearly identified clinical perspectives having included in vivo evaluations on animal models of the corresponding diseases (see for instance Damgé et al, 1988, Fattal et al, 1989, Chiannikulchai et al, 1989, Chavany et al, 1992, Schwab et al, 1994, Brigger et al, 2004, Calvo et al, 2001a, Juenet et al, 2017, Fusser et al, 2019. Following such an approach has been reminded as an urgent necessity to make progress in clinical translation of nanomedicines in recent articles analysing the clinical output of the considerable amount of works done on nanomedicines , Venditto and Szoka, 2013, Dai et al, 2018.…”